IN2015DN01404A - - Google Patents

Info

Publication number
IN2015DN01404A
IN2015DN01404A IN1404DEN2015A IN2015DN01404A IN 2015DN01404 A IN2015DN01404 A IN 2015DN01404A IN 1404DEN2015 A IN1404DEN2015 A IN 1404DEN2015A IN 2015DN01404 A IN2015DN01404 A IN 2015DN01404A
Authority
IN
India
Prior art keywords
factor
modified
polypeptides
forms
zymogen
Prior art date
Application number
Other languages
English (en)
Inventor
Edwin L Madison
Christopher Thanos
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of IN2015DN01404A publication Critical patent/IN2015DN01404A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
IN1404DEN2015 2012-07-25 2013-03-15 IN2015DN01404A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261741806P 2012-07-25 2012-07-25
PCT/US2013/032616 WO2014018120A1 (fr) 2012-07-25 2013-03-15 Polypeptides modifiés du facteur x et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2015DN01404A true IN2015DN01404A (fr) 2015-07-03

Family

ID=48040462

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1404DEN2015 IN2015DN01404A (fr) 2012-07-25 2013-03-15

Country Status (18)

Country Link
US (2) US9145552B2 (fr)
EP (1) EP2877487B1 (fr)
JP (2) JP6363600B2 (fr)
KR (1) KR102049900B1 (fr)
CN (1) CN104755492A (fr)
AU (1) AU2013293573B2 (fr)
BR (1) BR112015001628A2 (fr)
CA (1) CA2879785C (fr)
EA (1) EA028865B1 (fr)
ES (1) ES2704083T3 (fr)
HK (1) HK1210790A1 (fr)
IL (1) IL236449B (fr)
IN (1) IN2015DN01404A (fr)
MX (1) MX365612B (fr)
NZ (1) NZ703148A (fr)
SG (1) SG11201500579SA (fr)
WO (1) WO2014018120A1 (fr)
ZA (1) ZA201500097B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735439B1 (fr) 2004-04-12 2011-11-23 Catalyst Biosciences, Inc. Clivage du vegf et du récepteur du vegf par mt-sp1 de type sauvage et mutant
US20070093443A1 (en) 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
KR101476458B1 (ko) 2006-07-05 2015-01-05 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
WO2008127702A2 (fr) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Polypeptides du facteur vii modifiés et leurs utilisations
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
CN105579468A (zh) 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
DK3096779T3 (da) * 2014-01-24 2020-02-24 Pfizer Sammensætninger og fremgangsmåder til behandling af intracerebral blødning
US10444715B2 (en) * 2014-05-01 2019-10-15 Belkin International, Inc. Controlling settings and attributes related to operation of devices in a network
LT3149163T (lt) 2014-05-26 2020-09-25 Academisch Ziekenhuis Leiden Prohemostatiniai baltymai, skirti kraujavimo gydymui
US10676730B2 (en) 2015-01-07 2020-06-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Mutated factor X polypeptides and uses thereof for the treatment of haemophilia
EP3328998A1 (fr) 2015-07-27 2018-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides mutés du facteur x et leurs utilisations pour le traitement de l'hémophilie
WO2017118910A1 (fr) * 2016-01-07 2017-07-13 Eio Biomedical Ltd Procédés, compositions et kits pour réduire les adhésions tissulaires
FR3050992A1 (fr) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement Mutants du facteur x
FR3077296A1 (fr) * 2018-02-01 2019-08-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Dimeres de variants du facteur x
WO2019201868A1 (fr) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Protéine de fusion à base de facteur de coagulation contentant un polypeptide d'extension de demi-vie
WO2021030787A1 (fr) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Polypeptides de facteur vii modifiés pour une administration sous-cutanée et un traitement à la demande
EP3831843A1 (fr) * 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland Agent hémostatique et ses utilisations
WO2023086388A1 (fr) * 2021-11-09 2023-05-19 YewSavin, Inc. Compositions et méthodes pour traiter un saignement et des troubles de saignement
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116426510B (zh) * 2023-06-13 2023-09-22 北京沃森赛瑟生物技术有限公司 含修饰Xa因子的利伐沙班检测试剂盒及检测方法与应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AU6673898A (en) 1997-03-07 1998-09-22 Washington University Factor x variant
US20030207402A1 (en) 1997-08-22 2003-11-06 Erhard Kopetzki Autocatalytically activatable zymogenic precursors of proteases and their use
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
US20030186329A1 (en) 1999-03-22 2003-10-02 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
WO2002033089A2 (fr) 2000-10-05 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteur de la voie de facteur tissulaire d'ixodes scapularis
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
WO2003004681A2 (fr) 2001-07-03 2003-01-16 Dendreon San Diego Llc Molecules d'acides nucleiques codant une serine protease 20 transmembranaire, les polypeptides codes et les methodes correspondantes
WO2003031585A2 (fr) 2001-10-09 2003-04-17 Dendreon Corporation Molecules d'acide nucleique codant une serine protease transmembranaire 25, polypeptides codes et procedes connexes
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
AU2002357004A1 (en) 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20050112579A1 (en) 2002-07-02 2005-05-26 Dendreon San Diego Llc, A Delaware Corporation Nucleic acid molecules encoding serine protease 16, the encoded polypeptides and methods based thereon
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
AU2003282724B2 (en) 2002-10-02 2010-03-04 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
WO2005022330A2 (fr) 2003-08-27 2005-03-10 Jambo Networks, Inc. Systeme et procede permettant d'offrir des services de communication a des utilisateurs de dispositifs mobiles
WO2005023308A1 (fr) 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations de polypeptides dependant de la vitamine k et sulfoalkyl ether cyclodextrines
DE10350880A1 (de) 2003-10-31 2005-06-02 Roche Diagnostics Gmbh Verfahren zur Bestimmung eines Analyten mittels einer Extraktionsschicht
EP1735439B1 (fr) 2004-04-12 2011-11-23 Catalyst Biosciences, Inc. Clivage du vegf et du récepteur du vegf par mt-sp1 de type sauvage et mutant
US20060029590A1 (en) 2004-06-10 2006-02-09 Christopher Thanos Administration of neutral endopeptidase to treat inflammatory bowel disease
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
EP1726643A1 (fr) 2005-05-27 2006-11-29 Direvo Biotech AG Méthode pour la provision, l'identification, la sélection des protéases avec une sensititivité modifiée contre des substances modulatrices
EP1728798A1 (fr) 2005-06-01 2006-12-06 ZLB Behring GmbH Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées
US20070093443A1 (en) 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (fr) 2006-02-21 2007-08-22 CSL Behring GmbH Polypeptides du facteur de coagulation X avec des propriétés d'activation modifiées
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
KR101476458B1 (ko) 2006-07-05 2015-01-05 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
WO2008127702A2 (fr) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Polypeptides du facteur vii modifiés et leurs utilisations
HUE052423T2 (hu) 2007-09-28 2021-04-28 Alexion Pharma Inc Az XA faktor inhibitorok antidótumai és ezek alkalmazási módszerei
DK2202306T3 (da) 2007-10-09 2013-01-21 Chemo Sero Therapeut Res Inst Rekombinant faktor x uden glycosylering og fremgangsmåde til fremstilling deraf
US20110104788A1 (en) 2008-02-07 2011-05-05 Andrew Baker Modulation of Adenoviral Tropism
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
EP2444491B1 (fr) * 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Facteur IX de coagulation humain hyperglycosylé
DK2337849T3 (en) 2008-09-15 2018-10-01 Uniqure Biopharma B V FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
WO2010117729A1 (fr) 2009-03-30 2010-10-14 Portola Pharmaceuticals, Inc. Antidotes pour des inhibiteurs du facteur xa et leurs procédés d'utilisation
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2013049804A1 (fr) 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions et procédés pour moduler l'homéostasie
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用

Also Published As

Publication number Publication date
NZ703148A (en) 2016-08-26
IL236449B (en) 2019-02-28
EA201500172A1 (ru) 2015-09-30
AU2013293573B2 (en) 2016-10-27
CA2879785C (fr) 2019-06-18
EA028865B1 (ru) 2018-01-31
HK1210790A1 (en) 2016-05-06
CN104755492A (zh) 2015-07-01
US9856467B2 (en) 2018-01-02
US9145552B2 (en) 2015-09-29
ES2704083T3 (es) 2019-03-14
US20140030247A1 (en) 2014-01-30
AU2013293573A1 (en) 2015-02-05
JP6363600B2 (ja) 2018-07-25
SG11201500579SA (en) 2015-02-27
EP2877487A1 (fr) 2015-06-03
KR20160073937A (ko) 2016-06-27
WO2014018120A1 (fr) 2014-01-30
MX2015001083A (es) 2015-04-08
KR102049900B1 (ko) 2019-11-28
MX365612B (es) 2019-06-07
IL236449A0 (en) 2015-02-26
EP2877487B1 (fr) 2018-10-17
JP2015524801A (ja) 2015-08-27
ZA201500097B (en) 2016-09-28
JP2018183147A (ja) 2018-11-22
US20140234290A1 (en) 2014-08-21
BR112015001628A2 (pt) 2017-11-07
CA2879785A1 (fr) 2014-01-30

Similar Documents

Publication Publication Date Title
IN2015DN01404A (fr)
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
AU335765S (en) Tile spacer
AU345145S (en) Bottle
UY34254A (es) Proteínas y péptidos modificados.
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
AU343235S (en) Bottle
MY162837A (en) Modified relaxin polypeptides and their uses
AU339376S (en) Sterilizing case
AU344326S (en) Bottle
AU335240S (en) Cover
AU347955S (en) Audio system
AU333604S (en) Remote control
AU337524S (en) Bottle
AU345141S (en) Bottle
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
AU343226S (en) Bottle
AU342435S (en) Covered pitcher
AU335860S (en) Trimming device
AU339266S (en) Chair
AU338124S (en) Remote control
TN2013000056A1 (en) Modified relaxin polypeptides and their uses
AU337867S (en) External angle for cement rendering
AU336059S (en) Tile clamp
AU334592S (en) Tile spacer spindle